^
No biomarker
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive
:
A1
BeiGene Press Release - 1wk
No biomarker
Small Lymphocytic Lymphoma
ICP-022
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
rituximab + ibrutinib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
venetoclax
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
idelalisib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
ibrutinib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
acalabrutinib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
PCR
Sensitive
:
A2
No biomarker
Small Lymphocytic Lymphoma
FCR
Sensitive
:
A2
No biomarker
Small Lymphocytic Lymphoma
alemtuzumab
Sensitive
:
A2
No biomarker
Small Lymphocytic Lymphoma
rituximab
Sensitive
:
A2
No biomarker
Small Lymphocytic Lymphoma
obinutuzumab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive
:
A2
No biomarker
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
rituximab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
ibrutinib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
ibrutinib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
ofatumumab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
ofatumumab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
idelalisib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
idelalisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
venetoclax
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our